covax-19 covax-19 covax-19 (or spikogen) is the result of a collaboration between vaxine and cinnagen, a private company with operations in the middle east. covax-19 is a recombinant protein-based covid-19 vaccine developed by south australian-based biotech company vaxine. it is under clinical trial in collaboration with the iranian company cinnagen. covax-19vaccine descriptiontargetsars-cov-2vaccine typeprotein subunitclinical datatrade namesspikogenroutes ofadministrationintramuscularlegal statuslegal status full and emergency authorisations full list of covax-19 authorisations part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal medical uses it requires two doses 21 days apart given by intramuscular injection. pharmacology covax-19 is a recombinant protein subunit. history vaxine began work on a covid-19 vaccine in january 2020. after developing a number of different types of vaccines, the company decided to focus on a "recombinant protein-based vaccine". a phase 1 human trial started in june 2020. the phase 1 trial involved 40 participants, 30 of whom received the vaccine. the remaining ten participants received a saline placebo. phases 2 and 3 clinical trials of covax-19 are being conducted in iran under a co-operation agreement. phase 2 clinical trials started in may 2021 and phase 3 trials commenced in august 2021. in the phase 2 trials, 400 iranian volunteers were injected with either a placebo or the first dose of the vaccine. if the studies are successful, vaxine will produce the vaccine under the name covax-19 in australia and cinnagen will produce the vaccine under the name spikogen in iran. clinical trials clinical trials of covax-19 (spikogen) phase registration number start number of participants age of participants location ref total vaccine placebo i nct04453852 30 june 2020 40 30 10 18–65 years adelaide, australia ii irct20150303021315n23 30 may 2021 400 300 100 18+ years tehran, iran nct04944368 iii irct20150303021315n24 7 august 2021 16,876 12,657 4,219 18–50 years tehran, iran nct05005559 authorisations